中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 11
Nov.  2020
Turn off MathJax
Article Contents

Expression and significance of programmed death-1 and T-cell immunoglobulin-and mucin domain-3-containing molecule 3 in hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2020.11.011
Research funding:

 

  • Received Date: 2019-05-20
  • Published Date: 2020-11-20
  • Objective To investigate the expression and clinical significance of programmed death-1(PD-1) and T-cell immunoglobulin-and mucin domain-3-containing molecule 3(TIM-3) in hepatocellular carcinoma(HCC).Methods The paraffin blocks of HCC tissue and adjacent tissue(> 1 cm from the tumor margin) were collected from 46 patients with HCC who underwent surgical treatment in No.900 Hospital of The Joint Service and Security Force of The Chinese People's Liberation Army from January 2013 to December 2015.Immunohistochemistry was used to measure the expression of PD-1 and TIM-3,and their association with clinicopathological features and prognosis was analyzed.The Wilcoxon test was used for comparison of paired ranked data,and a Spearman correlation analysis was used to investigate the correlation between ranked data; the Kaplan-Meier method was used for survival analysis,and the log-rank test was used for comparison of survival rates between groups; the Cox regression model was used to perform a multivariate analysis.Results The expression levels of PD-1 and TIM-3 in HCC tissue were higher than those in adjacent tissue(both P<0.05).PD-1 was mainly localized in lymphocytes and TIM-3 was mainly localized in tumor-associated macrophages.The expression of PD-1 was positively correlated with that of TIM-3 in HCC tissue(rs=0.397,P=0.006).The expression level of PD-1 in HCC tissue was associated with tumor size(rs=0.480,P=0.001),portal vein tumor thrombus(rs=0.307,P=0.038),and TNM stage(rs=0.534,P <0.001),and the expression level of TIM-3 was associated with portal vein tumor thrombus(rs=0.301,P=0.042),degree of pathological differentiation(rs=0.356,P=0.015),and TNM stage(rs=0.416,P=0.004).For the patients with HCC,the 1-,3-,and 5-year overall survival rates were89.1%,56.5%,and 34.4%,respectively,and the 1-,3-,and 5-year disease-free survival rates were 52.2%,21.7%,and 10.9%,respectively.The multivariate analysis showed that degree of pathological differentiation(hazard ratio [HR]=4.723,95% confidence interval [CI]:1.618-7.684,P=0.001),tumor size(HR=3.234,95% CI:1.327-7.883,P=0.010),TNM stage(HR=3.254,95% CI:1.076-9.835,P=0.037),and expression level of TIM-3(HR=0.572,95% CI:0.329-0.995,P=0.048) were independent prognostic factors for the overall survival of HCC patients,and degree of pathological differentiation(HR=2.945,95% CI:1.527-5.682,P=0.001) and TNM stage(HR=2.074,95% CI:1.259-9.793,P=0.016) were independent prognostic factors for the disease-free survival of HCC patients.Conclusion High expression levels of both PD-1 and TIM-3 are observed in HCC tissue,and PD-1 and TIM-3 may be involved in the progression and poor prognosis of HCC patients.

     

  • loading
  • [1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
    [2] CHEN W,ZHENG R,BAADE PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
    [3] RENG ZG. Immunotherapy for hepatocellular carcinoma[J]. J Clin Hepatol,2018,34(7):1371-1373.(in Chinese)任正刚.肝细胞癌的免疫治疗[J].临床肝胆病杂志,2018,34(7):1371-1373.
    [4] BAGHDADI M,JINUSHI M. The impact of the TIM gene family on tumor immunity and immunosuppression[J]. Cell Mol Immunol,2014,11(1):41-48.
    [5] SACHDEVA M,CHAWLA YK,ARORA SK. Immunology of hepatocellular carcinoma[J]. World J Hepatol,2015,7(17):2080-2090.
    [6] LAN F,LI RM,YANG LY,et al. Anti-tumor immune therapy with programmed death-1 and its ligand inhibitors:research advances[J]. J Int Pharm Res,2016,43(5):813-817.(in Chinese)兰芬,李睿旻,阳凌燕,等.程序性细胞死亡蛋白1及其配体抑制剂抗肿瘤免疫治疗进展[J].国际药学研究杂志,2016,43(5):813-817.
    [7] JOYCE JA,FEARON DT. T cell exclusion,immune privilege,and the tumor microenvironment[J]. Science,2015,348(6230):74-80.
    [8] MONNEY L,SABATOS CA,GAGLIA JL,et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease[J]. Nature,2002,415(6871):536-541.
    [9] ANDERSON AC,ANDERSON DE,BREGOLI L,et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells[J]. Science,2007,318(5853):1141-1143.
    [10] JU Y,HOU N,MENG J,et al. T cell immunoglobulin-and mucin-domain-containing molecule-3(Tim-3)mediates natural killer cell suppression in chronic hepatitis B[J]. J Hepatol,2010,52(3):322-329.
    [11] WU W,SHI Y,LI S,et al. Blockade of Tim-3 signaling restores the virus-specific CD8+T-cell response in patients with chronic hepatitis B[J]. Eur J Immunol,2012,42(5):1180-1191.
    [12] ANDERSON AC. Tim-3,a negative regulator of anti-tumor immunity[J]. Curr Opin Immunol,2012,24(2):213-216.
    [13] PATEL J,BOZEMAN EN,SELVARAJ P. Taming dendritic cells with TIM-3:Another immunosuppressive strategy used by tumors[J]. Immunotherapy,2012,4(12):1795-1798.
    [14] HARDING JJ,EL DIKA I,ABOU-ALFA GK. Immunotherapy in hepatocellular carcinoma:Primed to make a difference?[J]. Cancer,2016,122(3):367-377.
    [15] JI M,LIU Y,LI Q,et al. PD-1/PD-L1 pathway in nonsmall-cell lung cancer and its relation with EGFR mutation[J]. J Transl Med,2015,13:5.
    [16] FREEMAN-KELLER M,WEBER JS. Anti-programmed death receptor 1 immunotherapy in melanoma:Rationale,evidence and clinical potential[J]. Ther Adv Med Oncol,2015,7(1):12-21.
    [17] HUANG RY,EPPOLITO C,LELE S,et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+T cell signaling and dampen antitumor immunity in a murine ovarian cancer model[J]. Oncotarget,2015,6(29):27359-27377.
    [18] SHINOHARA T,TANIWAKI M,ISHIDA Y,et al. Structure and chromosomal localization of the human PD-1 gene(PDCD1)[J]. Genomics,1994,23(3):704-706.
    [19] FRANCISCO LM,SAGE PT,SHARPE AH. The PD-1 pathway in tolerance and autoimmunity[J]. Immunol Rev,2010,236:219-242.
    [20] LIU LX,CAI W. Current situation and prospect of immunotherapy for hepatocellular carcinoma[J]. Chin J Dig Surg,2020,19(2):119-122.(in Chinese)刘连新,蔡伟.肝细胞癌免疫治疗的现状和展望[J].中华消化外科杂志,2020,19(2):119-122.
    [21] FIFE BT,PAUKEN KE,EAGAR TN,et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal[J]. Nat Immunol,2009,10(11):1185-1192.
    [22] ZHU C,ANDERSON AC,KUCHROO VK. TIM-3 and its regulatory role in immune responses[J]. Curr Top Microbiol Immunol,2011,350:1-15.
    [23] SOLINAS G,GERMANO G,MANTOVANI A,et al. Tumorassociated macrophages(TAM)as major players of the cancer-related inflammation[J]. J Leukoc Biol,2009,86(5):1065-1073.
    [24] BISWAS SK,MANTOVANI A. Macrophage plasticity and interaction with lymphocyte subsets:Cancer as a paradigm[J].Nat Immunol,2010,11(10):889-896.
    [25] MASSAGUE J. TGFbeta in cancer[J]. Cell,2008,134(2):215-230.
    [26] YAN WJ. TGFβenhanced Tim-3 expression on macrophages fosters M2-like alternative activation contributing to HCC[D].Jinan:Shandong University,2014.(in Chinese)阎文江.Tim-3在肿瘤相关巨噬细胞极化及肝细胞肝癌进展中的作用及机制研究[D].济南:山东大学,2014.
    [27] LI Z,LI N,LI F,et al. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma[J]. Pubmed, 2016, 95(52):e5749.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (4487) PDF downloads(77) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return